JP2020147501A - 抗がん剤の副作用軽減剤 - Google Patents
抗がん剤の副作用軽減剤 Download PDFInfo
- Publication number
- JP2020147501A JP2020147501A JP2019043591A JP2019043591A JP2020147501A JP 2020147501 A JP2020147501 A JP 2020147501A JP 2019043591 A JP2019043591 A JP 2019043591A JP 2019043591 A JP2019043591 A JP 2019043591A JP 2020147501 A JP2020147501 A JP 2020147501A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- side effect
- cancer
- reducing agent
- blowfish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 101
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 52
- 239000003638 chemical reducing agent Substances 0.000 title claims abstract description 37
- 241001441724 Tetraodontidae Species 0.000 claims abstract description 43
- 235000021067 refined food Nutrition 0.000 claims abstract description 20
- 208000003251 Pruritus Diseases 0.000 claims abstract description 14
- 230000007803 itching Effects 0.000 claims abstract description 12
- 210000004209 hair Anatomy 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 201000004384 Alopecia Diseases 0.000 claims abstract description 9
- 208000024963 hair loss Diseases 0.000 claims abstract description 8
- 230000003676 hair loss Effects 0.000 claims abstract description 8
- 230000019612 pigmentation Effects 0.000 claims abstract description 8
- 230000008961 swelling Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 5
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 229940041181 antineoplastic drug Drugs 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 22
- 241001441723 Takifugu Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 230000001603 reducing effect Effects 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims 1
- 229930014626 natural product Natural products 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 description 28
- 235000013305 food Nutrition 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000037406 food intake Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940053867 xeloda Drugs 0.000 description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003648 hair appearance Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
Abstract
Description
[1]ふぐ皮の加工食品を有効成分として含有する、抗がん剤の副作用軽減剤。
[2]前記抗がん剤が、細胞障害性抗がん剤又は分子標的薬である、上記[1]に記載の副作用軽減剤。
[3]前記副作用が、頭髪等の脱毛、皮膚のそう痒感、皮膚への色素沈着又は皮膚のはれである、上記[1]又は[2]に記載の副作用軽減剤。
[4]前記加工食品がふぐ皮湯引きである、上記[1]〜[3]のいずれかに記載の副作用軽減剤。
[5]ふぐ皮の加工食品を、抗がん剤治療前の、抗がん剤治療中の、或いは抗がん剤治療後のがん患者に摂取させる工程を含んでなる、抗がん剤の副作用軽減方法。
[6]副作用軽減剤の製造のための、副作用軽減剤としての、或いは上記[4]に記載の方法における、ふぐ皮の加工食品の使用。
本発明の副作用軽減剤は、例えば、食品(例えば、食品組成物)、飼料(ペットフード含む)等の形態で提供することができる。本発明の副作用軽減剤を食品として提供する場合には、本発明の有効成分であるふぐ皮の加工食品をそのまま食品として提供することができ、あるいはそれを食品に含有させて提供することができる。
ふぐ皮湯引きの摂取による副作用軽減効果を評価した。ふぐ皮湯引きは「玄品ふぐのふぐ皮湯引き」(株式会社関門海製)を用いた(以下、試験例2〜4において同様)。
・被験者A:女性、乳がん患者(ステージ3)
・治療状況:化学療法1(AC療法:ドキソルビシン及びシクロホスファミド)を約3か月(4クール)、次いで化学療法2(ドセタキセル及びハーセプチン)を約3か月(4クール)
※1クールは3週間で構成されている。第1週目に薬剤を投与し、第2週目及び第3週目は休薬する。
下記被験者について、ふぐ皮湯引きの摂取による副作用軽減効果を評価した。
・被験者B:女性、乳がん患者(骨盤転移あり、ステージ4)
・治療状況:化学療法3(ランマーク及びフェソロデックスを4週間おきにそれぞれ皮下及び筋注投与)
下記被験者について、ふぐ皮湯引きの摂取による副作用軽減効果を評価した。
・被験者C:男性、小腸がん患者(腹膜播種あり、ステージ4)
・治療状況:化学療法4(オキサリプラチン静脈投与及びゼローダ経口投与、4か月後にゼローダ経口投与のみに変更)
下記被験者について、ふぐ皮湯引きの摂取による副作用軽減効果を評価した。
・被験者D:女性、脳腫瘍患者(松果体腫瘍)
・治療状況:化学療法5(イホマイド、シスプラチン及びエトポシドを合計8回投与)、脳への放射線治療並びに腫瘍摘出手術
Claims (5)
- ふぐ皮の加工食品を有効成分として含有する、抗がん剤の副作用軽減剤。
- 前記抗がん剤が、細胞障害性抗がん剤又は分子標的薬である、請求項1に記載の副作用軽減剤。
- 前記副作用が、頭髪等の脱毛、皮膚のそう痒感、皮膚への色素沈着又は皮膚のはれである、請求項1又は2に記載の副作用軽減剤。
- 前記加工食品がふぐ皮湯引きである、請求項1〜3のいずれか一項に記載の副作用軽減剤。
- ふぐ皮の加工食品を、抗がん剤治療前の、抗がん剤治療中の、或いは抗がん剤治療後のがん患者に摂取させる工程を含んでなる、抗がん剤の副作用軽減方法(但し、ヒトに対する医療行為を除く)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019043591A JP7338835B2 (ja) | 2019-03-11 | 2019-03-11 | 抗がん剤の副作用軽減剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019043591A JP7338835B2 (ja) | 2019-03-11 | 2019-03-11 | 抗がん剤の副作用軽減剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020147501A true JP2020147501A (ja) | 2020-09-17 |
JP7338835B2 JP7338835B2 (ja) | 2023-09-05 |
Family
ID=72431692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019043591A Active JP7338835B2 (ja) | 2019-03-11 | 2019-03-11 | 抗がん剤の副作用軽減剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7338835B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020150796A (ja) * | 2019-03-18 | 2020-09-24 | 有限会社玄洋社 | 河豚皮食品及びその製造方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007504100A (ja) * | 2003-08-28 | 2007-03-01 | ナンジンバオシェンヤオイエヨウシャンゴンシ | フグi型コラーゲン抽出物の医学的且つ保険的使用及び当該抽出物の製造方法 |
KR100760875B1 (ko) * | 2006-06-21 | 2007-10-04 | 부경대학교 산학협력단 | 멜라닌 생성 억제 피부미백용 화장품 조성물 |
CN101607982A (zh) * | 2008-06-19 | 2009-12-23 | 陈栋梁 | 一种具有美白效果的鱼皮胶原肽及其制备工艺和用途 |
KR101736490B1 (ko) * | 2016-08-04 | 2017-05-17 | 주식회사 빅스마일푸드 | 콜라겐 추어탕 제조방법 및 이에 의해 제조된 콜라겐 추어탕 |
JP2017137247A (ja) * | 2016-02-01 | 2017-08-10 | 株式会社太陽 | 経口免疫機能調整剤及び免疫機能調整用食品 |
-
2019
- 2019-03-11 JP JP2019043591A patent/JP7338835B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007504100A (ja) * | 2003-08-28 | 2007-03-01 | ナンジンバオシェンヤオイエヨウシャンゴンシ | フグi型コラーゲン抽出物の医学的且つ保険的使用及び当該抽出物の製造方法 |
KR100760875B1 (ko) * | 2006-06-21 | 2007-10-04 | 부경대학교 산학협력단 | 멜라닌 생성 억제 피부미백용 화장품 조성물 |
CN101607982A (zh) * | 2008-06-19 | 2009-12-23 | 陈栋梁 | 一种具有美白效果的鱼皮胶原肽及其制备工艺和用途 |
JP2017137247A (ja) * | 2016-02-01 | 2017-08-10 | 株式会社太陽 | 経口免疫機能調整剤及び免疫機能調整用食品 |
KR101736490B1 (ko) * | 2016-08-04 | 2017-05-17 | 주식회사 빅스마일푸드 | 콜라겐 추어탕 제조방법 및 이에 의해 제조된 콜라겐 추어탕 |
Non-Patent Citations (1)
Title |
---|
藤井真ほか: "化学療法と栄養管理", ヒューマンニュートリション, JPN6023000548, 2014, pages 67 - 71, ISSN: 0004964712 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020150796A (ja) * | 2019-03-18 | 2020-09-24 | 有限会社玄洋社 | 河豚皮食品及びその製造方法 |
JP7235544B2 (ja) | 2019-03-18 | 2023-03-08 | 有限会社玄洋社 | 河豚皮食品の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP7338835B2 (ja) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2444355C2 (ru) | Способы лечения с применением цитруллина | |
CN111479577A (zh) | 用于增强癌症放疗的组合物和方法 | |
CN103168993A (zh) | 用于防治便秘并可作为膳食纤维组件膳的纤维营养制剂 | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
JP7338835B2 (ja) | 抗がん剤の副作用軽減剤 | |
CN1900255A (zh) | 男性健美长寿液 | |
CN104906539B (zh) | 一种防治化疗引起的延迟性恶心呕吐的中药组合物及其应用 | |
JP7029141B2 (ja) | 末梢神経障害改善用組成物 | |
CN105560221A (zh) | 巯基化合物在制备治疗恶性肿瘤药物中的应用 | |
KR100363998B1 (ko) | 퇴행성관절염 개선 음료 조성물 및 이의 제조 방법 | |
CN103202861A (zh) | 酪酸梭菌、双歧杆菌二联活菌制剂与抗癌药物组合在制备治疗肠癌药物中的应用 | |
KR20170103380A (ko) | 피부의 미백과 잔주름 개선용 조성물 | |
CN109260235A (zh) | 一种组合物在制备防治便秘药物或保健品中的应用 | |
CN110876803B (zh) | 一种包含乳蛋白和油酸的药物组合物 | |
Hemming et al. | Understanding cachexia and excessive weight loss in cancer | |
WO2014068296A1 (en) | Fat loss composition | |
KR102517569B1 (ko) | 독도새우 유래 유산균 및 이를 포함하는 조성물 | |
JP2005320261A (ja) | 制癌剤 | |
RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
CN106727716A (zh) | 一种肿瘤康复汤及其制法 | |
CN102671058A (zh) | 治疗呕吐中药口服液及制备方法 | |
CN109602876B (zh) | 一种治疗食道癌的中药组合物及其制备方法 | |
JPH0235057A (ja) | 機能性食品 | |
JP2017222587A (ja) | 変形性関節症予防用組成物、変形性関節症予防用食品組成物、変形性関節症予防用食品添加物及び変形性関節症予防用医薬 | |
RU2159116C1 (ru) | Способ активационной терапии заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230517 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230815 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7338835 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |